RECRUITING

Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Frailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality. Nicotinamide adenine dinucleotide (NAD) is a critical co-factor needed for many cellular processes. The natural levels of NAD decline aging and this has been linked to physical performance decline in animals. Human trials have demonstrated that nicotinamide riboside (NR), a form of vitamin B3, is safe and effectively increases NAD+ levels. In animal studies, NR improves treadmill performance and muscle quality. Here the investigators propose a double-blind randomized control trial to assess the benefits of NR supplementation on human muscle function and physiology. The investigators anticipate the research findings will support the use of this nutritional supplement to improve the health of Veterans during aging.

Official Title

Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans

Quick Facts

Study Start:2023-09-01
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04691986

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ages 65-85
  2. * Male or female
  3. * Any race
  4. * Ability to use an exercise bike
  5. * Medically cleared for muscle biopsy
  1. * Severe Co-morbidity
  2. * examples include, but not limited to:
  3. * congestive heart failure class equal to or above III
  4. * chronic obstructive pulmonary disorder (COPD) gold stage IV
  5. * chronic kidney disease equal to or above stage
  6. * A VA-SLUMS cognitive screen score of less than or equal to 20
  7. * Body mass index greater than or equal to 40

Contacts and Locations

Study Contact

Kenneth L Seldeen, PhD
CONTACT
(716) 888-4869
Kenneth.Seldeen@va.gov

Principal Investigator

Kenneth L Seldeen, PhD
PRINCIPAL_INVESTIGATOR
Kansas City VA Medical Center, Kansas City, MO

Study Locations (Sites)

Kansas City VA Medical Center, Kansas City, MO
Kansas City, Missouri, 64128-2226
United States

Collaborators and Investigators

Sponsor: VA Office of Research and Development

  • Kenneth L Seldeen, PhD, PRINCIPAL_INVESTIGATOR, Kansas City VA Medical Center, Kansas City, MO

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-01
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2023-09-01
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • muscle
  • strength
  • endurance
  • gait speed
  • grip strength
  • frailty
  • muscle fibers
  • mitochondria
  • inflammation
  • resilience
  • aging

Additional Relevant MeSH Terms

  • Sarcopenia
  • Nicotinamide Adenine Dinucleotide Concentration
  • Muscle Quality and NAD+ Content